osimertinib
astrazeneca
['adaura', 'aura ,(-laura)']
 we won t have the answer as adaura never wanted to answer that very question of yours. if they had wanted they should have powered the study for os first and made obligatory to give osi at progression.
Medical Oncologist, department of oncology at the University hospital of Geneva (HUG). All opinions expressed here are my own